Holen Sie sich die Stockscreener-App
0.00
0.00%
0.00
Schlusskurs vom Vortag:
$0.00
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
Marktkapitalisierung:
$N/A
Einnahmen:
$1.65M
Nettoeinkommen (Verlust:
$-5.91M
KGV:
0.00
EPS:
-0.1707
Netto-Cashflow:
$-3.03M
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Firmenname
Vitro Biopharma, Inc.
Sektor
Branche
Telefon
(720) 859-4120
Adresse
4621 TECHNOLOGY DRIVE, GOLDEN
Vergleichen Sie VTRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VTRO | 0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Vitro Biopharma, Inc. Aktie (VTRO) Neueste Nachrichten
Vitro Diagnostics (OTCMKTS:VODG) and Tectonic Therapeutic (NASDAQ:TECX) Critical Comparison - Defense World
Biopharmaceutical Culture Media Industry Trends & Drivers - Economica
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2024 - Marketscreener.com
Top 5 In-Vitro Diagnostics [IVD] Companies, Worldwide by 2024 - Fortune Business Insights
[Updated] Biopharmaceutical Culture Media Market Size Analysis - Economica
6 cultured meat companies making waves - Labiotech.eu
Vitro Diagnostics (OTCMKTS:VODG) & Cidara Therapeutics (NASDAQ:CDTX) Critical Comparison - Defense World
FDA’s lab-developed test rule could be first test of agency’s power post-Chevron - BioPharma Dive
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
Financial Survey: Innate Pharma (NASDAQ:IPHA) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
New In Vitro Data Showing Matinas BioPharma's LNC Platform - GlobeNewswire
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES ... - Yahoo Finance
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 - Yahoo Finance
Contrasting Vitro Diagnostics (OTCMKTS:VODG) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
Vitro Biopharma, Inc. announced that it has received $0.3 million in funding - Marketscreener.com
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit - Yahoo Finance
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights - PR Newswire
Best Biotech Stocks to Buy in 2024 - The Motley Fool
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 - StockTitan
ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data - ScienceDirect.com
Fapon Empowers Indian IVD Manufacturers at Medical Fair India 2024 - PR Newswire
Why Redhill Biopharma Stock Is Moving HigherRedhill Biopharma (NASDAQ:RDHL) - Benzinga
Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside - CNBC
Swiss investment firm denies acquisition bid for Boryung Biopharma - KBR
Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc. - PR Newswire
Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments - StockTitan
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results - Yahoo Finance
Navigate BioPharma Services, Inc. Announces Collaboration with BD (Becton, Dickinson and Company) to Advance Capabilities for Clinical Phases of Drug Development - PR Newswire
IPO Update: Vitro Biopharma Aims For $10 Million U.S. IPO (VTRO) - Seeking Alpha
Startup aims to make lab-grown human eggs, transforming options for creating families - NPR
VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - Renaissance Capital
CYPRE’S 3D in Vitro Platform Advances New Insights into the Tumor Microenvironment, Drives Data in 30 Days for Clients - Business Wire
Why Matinas BioPharma Stock Is Sinking Today - Yahoo Finance
Global Stem Cells Market Research Report 2023: Implications - GlobeNewswire
This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF - STAT
Who are the leading innovators in in-vitro T-cell activation for the pharmaceutical industry? - Pharmaceutical Technology
In Vitro Glycoengineering – Suitability For BioPharma Manufacturing - BioProcess Online
Is Vitro Biopharma Inc. IPO a Good Buy? - Benzinga
Vitro Biopharma Names Chris Furman Chief Executive Officer - Yahoo Finance
Everlife-backed CPC Diagnostics buys i-chroma brand biz of South Korea-based company - VCCircle
The 10 most innovative biotech companies in 2022 - Fast Company
Business of Biotechniques 2022 - BioTechniques
Schrödinger picks up protein crystallographer XTAL BioStructures - Fierce Biotech
Adagio Therapeutics Inc. (NASDAQ: ADGI) Offers Update About In Vitro Analysis On ADG20's Neutralizing Activity Against Omicron - BP Journal
43 Top Biopharma Startups and Companies in Germany - EU-Startups
Emulate enhances tech aimed at supporting disease research and drug development - BioPharma-Reporter.com
RGBPRegen BioPharma, Inc. Latest Stock News & Market Updates - StockTitan
Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine - StockTitan
This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines - Science
Cocrystal Pharma Inc (NASDAQ: COCP)'s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Vitro Activity Against the SARS-CoV-2 Delta and Gamma Variants - BP Journal
Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - Pharmaceutical Online
Finanzdaten der Vitro Biopharma, Inc.-Aktie (VTRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
Kapitalisierung:
|
Volumen (24h):